We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Genetic Causes of Bowel Cancer Clarified

By LabMedica International staff writers
Posted on 14 Jul 2016
Print article
Image: The E220 focused-ultrasonicator for DNA fragmentation (Photo courtesy of Covaris).
Image: The E220 focused-ultrasonicator for DNA fragmentation (Photo courtesy of Covaris).
Colorectal cancer (CRC) displays a complex pattern of inheritance and it is postulated that much of the missing heritability of CRC is enshrined in high-impact rare alleles, which are mechanistically and clinically important.

A landmark study has given the most detailed picture yet of the genetics of bowel cancer, the UK's fourth most common cancer, and the genetic architecture of CRC susceptibility encompasses a broad spectrum of risk, from rare, highly penetrant germline mutations associated with well-characterized syndromes to common polymorphisms, each individually conferring small risk.

Scientists at the Institute of Cancer Research (London, UK) and their colleagues included in a study 1,028 unrelated patients (559 male) with CRC, aged ≤55 years at diagnosis (mean age 48.7 ± 6.0), who had at least one first-degree relative with CRC, ascertained between 2003 and 2011. All the patients were UK residents and had self-reported European ancestry. Germline DNA was isolated from EDTA-venous bloods using standard methods and picogreen quantified. The controls comprised 1,644 healthy individuals from the UK and an additional 670 individuals, all who were sequenced.

A Covaris E Series instrument (Covaris Inc., Woburn, MA, USA) was used to fragment 1 μg of DNA from each individual. Illumina’s Truseq 62 Mb expanded exome enrichment kit was used to prepare indexed paired-end libraries, 2 × 100 bp sequencing was performed using the HiSeq2000 technology (Illumina, San Diego, CA, USA). The scientists also performed read mapping and variant analysis, sample-level quality control, ExomeArray concordance and other methodologies.

The investigators found that added together, all the discovered variants in the known bowel cancer genes accounted for less than a third of familial cases of bowel cancer, those occurring in people whose close relatives had already developed it. The rest of the familial cases must therefore be caused largely by minor DNA variations that in combination add up to increase risk, with environmental factors also contributing. For an individual person, the risk of developing bowel cancer comes from a mix of inherited risk through their genes and environmental risk, which is caused by non-genetic factors such as lifestyle. Around 12% of cases occur in people with a family history of bowel cancer, with inherited mutations in known cancer-causing genes such as Adenomatous Polyposis Coli (APC) and MutL Homolog 1(MLH1) often playing a major role.

Richard S.Houlston, MD, PhD, a Professor of Molecular and Population Genetics and senior author of study, said, “Our study is the largest ever conducted of the genetics of bowel cancer, and sets out a detailed map of the disease that could lead us to new ways of treating or preventing it. Each cancer gene that has been discovered, or common genetic variant that we will continue to uncover, provides us with new insights into the underlying biology of the disease, and increases our ability to assess people for their risk.” The study was published on June 22, 2016, in the journal Nature Communications.

Related Links:
Institute of Cancer Research
Covaris
Illumina
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Automated Blood Typing System
IH-500 NEXT
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA
New
Newborn Screening Test
NeoMass AAAC 3.0

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.